Kintera

Kinterra Therapeutics is a precision medicine company focused on the discovery and development of next-generation small molecule kinase inhibitors for patients with cancer and rare diseases. The company utilizes a proprietary platform that integrates structural biology, medicinal chemistry, and translational biology to target well-validated but difficult-to-drug kinases. Their lead programs are designed to address specific resistance mutations in the KIT and FLT3 kinases, aiming to provide more effective and durable treatments for conditions such as systemic mastocytosis and acute myeloid leukemia. Kinterra is backed by prominent life science investors, including OrbiMed and F-Prime Capital, and is headquartered in San Diego.